Stock of the Day

Zimmer Biomet (ZBH)

$94.51

+$2.74 (+3.0%)

Market Cap: $17.50B

About Zimmer Biomet

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E

.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Zimmer Biomet Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

• Recent earnings results demonstrate strong fundamental performance, with the company reporting $2.07 earnings per share for the most recent quarter, which beat the consensus estimate of $2.01 by $0.06, while revenue of $2.18 billion also exceeded analyst expectations of $2.13 billion, indicating robust demand for its orthopedic products.
• The stock currently trades at $92.09, which is significantly below the consensus price target of $103.33, suggesting substantial upside potential as analysts maintain a "Hold" consensus rating with several firms, including UBS Group and Stifel Nicolaus, issuing "Buy" ratings with higher price targets.
• Zimmer Biomet Holdings, Inc. offers a stable income stream for investors through its dividend, which has a current yield of 1.08%, with a recent declaration of $0.24 per share quarterly, providing a consistent return on investment alongside potential capital appreciation.
• The company exhibits low volatility relative to the broader market, as indicated by a beta of 0.49, which means its stock price tends to fluctuate less than the overall market, making it a potentially defensive holding for investors seeking stability in the healthcare sector.
• Institutional investors continue to show confidence in the company, with major firms like BlackRock Inc. establishing new positions and State Street Corp increasing its holdings, reflecting a broader trend of institutional accumulation that often signals long-term value recognition.

Zimmer Biomet Bear Case

Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

• Insider selling activity has been notable recently, with executives such as Kevin R. Thornal and Chad Phipps selling thousands of shares in September 2026, which can signal a lack of confidence in the stock's near-term performance or a desire to lock in gains.
• The stock has experienced significant price volatility and recent declines, having hit a 52-week low of $79.12 in May 2026 and trading down 1.4% in recent sessions, indicating potential downward pressure and uncertainty in the market's perception of the company's value.
• Short interest has increased in recent months, with shares shorted rising to 9,745,945 as of September 30, 2026, representing a 13.63% month-to-month increase, which suggests that a growing number of traders are betting against the stock's price appreciation.
• The company's valuation, with a P/E ratio of 22.41, may be considered high relative to its growth prospects, especially given that the consensus rating remains a "Hold" rather than a "Buy," indicating that analysts are cautious about further upside potential at current price levels.
• Recent analyst actions, such as Zacks Research raising its rating from "strong sell" to "hold" in August 2025, suggest that while the stock may have improved, it still faces challenges that prevent a more positive outlook, and the overall consensus remains neutral rather than bullish.

Recent News

• Zimmer Biomet Extends THINK Surgical Distribution Deal for Knee Surgery Robot (finance.yahoo.com)
• Leerink Partners Sticks to Their Hold Rating for Zimmer Biomet Holdings (ZBH) (theglobeandmail.com)
• Zimmer Biomet Extends Limited Exclusive Distribution Agreement With THINK Surgical (rttnews.com)
• ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT (prnewswire.com)
• Surgical equipment & consumables - diversified stocks Q2 results: Benchmarking Zimmer Biomet (NYSE:ZBH) (msn.com)